Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

GLTO
Galecto, Inc. Common Stock
stock NASDAQ

At Close
Dec 5, 2025 3:59:30 PM EST
26.99USD+17.890%(+4.10)132,612
0.00Bid   0.00Ask   0.00Spread
Pre-market
Dec 5, 2025 8:38:30 AM EST
22.36USD-2.315%(-0.53)287
After-hours
Dec 5, 2025 4:11:30 PM EST
26.94USD-0.167%(-0.05)492
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 27, 2022
07:21AM EST  Galecto Publishes Results Showing Safety And Efficacy Of The GB0139 Inhaled Galectin-3 Inhibitor In Hospitalized COVID-19 Patients On Standard Of Care   Benzinga
07:00AM EST  Results Support Favorable Safety and Tolerability Profile and Target Engagement of GB0139 and Potential for GB0139 in Severe Lung Disease   GlobeNewswire Inc
Jan 5, 2022
08:00AM EST  Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the appointment of a highly experienced biotech and pharmaceuticals executive Stephanie Oestreich, PhD, MPA as Chief Business Officer, a newly-created position at Galecto.   GlobeNewswire Inc
Dec 20, 2021
08:04AM EST  Galecto Says Has Enrolled 10 Of Anticipated 16 Patients In Phase 2a MYLOX-1 Trial; Reiterates Expected Timing Of Multiple Data Readouts In 2022   Benzinga
08:00AM EST  Galecto Provides Enrollment Update on Phase 2a MYLOX-1 Trial and   GlobeNewswire Inc
Dec 13, 2021
08:03AM EST  Galecto Announces Preliminary Results For Oral Galectin-3 Inhibitor GB1211 In Part 1 Of Its Phase 1b/2a Liver Cirrhosis Trial; Says 'GB1211 observed to be safe and well tolerated in initial twelve randomized subjects'   Benzinga
08:00AM EST  GB1211 observed to be safe and well tolerated in initial twelve randomized subjects, including six hepatically impaired liver cirrhosis patients   GlobeNewswire Inc
Nov 5, 2021
09:33AM EDT  Galecto Q3 EPS $(0.50) Up From $(55.25) YoY   Benzinga
09:31AM EDT  Galecto Files For $200M Mixed Shelf Offering   Benzinga
Nov 2, 2021
11:26AM EDT  Galecto To Test GB1211 Combined with Roche's Tecentriq In First Line Lung Cancer Setting   Benzinga
10:54AM EDT  Galecto Announces Clinical Collaboration With Roche For Phase 2 Trial Of GB1211 In Combination With Atezolizumab In First Line Non-Small-Cell Lung Cancer   Benzinga
08:00AM EDT  Upcoming Phase 2 trial marks expansion of Galecto pipeline into oncology and provides opportunity for exploring the use of galectin-3 inhibitors in cancer   GlobeNewswire Inc
Oct 28, 2021
08:00AM EDT  Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a key opinion leader (KOL) webinar on BG1211 and its potential as a treatment for non-small cell lung cancer, on Monday, November 8, 2021 at 10:30am Eastern Time.   GlobeNewswire Inc
Oct 26, 2021
08:00AM EDT  Galecto to Present at Upcoming Investor Conferences   GlobeNewswire Inc
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 28, 2021
08:18AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive   Benzinga
08:16AM EDT  The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK To Develop Long-Acting HIV Treatments   Benzinga
Sep 15, 2021
08:30AM EDT  Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, the Companys Chief Executive Officer, will be presenting on Tuesday, September 28, 2021 at 8:40 AM ET and will be available for 1x1 meetings on the same date.   GlobeNewswire Inc
Sep 13, 2021
08:03AM EDT  Galecto Announces First Patient Treated In Phase 2 Trial Of Oral Galectin-3 Inhibitor GB1211 In Liver Cirrhosis   Benzinga
08:00AM EDT  Galecto Announces First Patient Treated in Phase 2 Trial of Oral   GlobeNewswire Inc
Aug 18, 2021
09:25AM EDT  Galecto Starts Dosing In Mid-Stage Myelofibrosis Trial   Benzinga
08:01AM EDT  Galecto Announces First Patient Treated In Phase 2a Trial Of Oral LOXL2 Inhibitor GB2064 In Myelofibrosis   Benzinga
08:00AM EDT  Galecto Announces First Patient Treated in Phase 2a Trial of the   GlobeNewswire Inc
07:38AM EDT  The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline   Benzinga
Aug 17, 2021
09:58AM EDT  Galecto Sponsored Study 'A Single and Repeat Dose Trial in Participants With Hepatic Impairment' Posted To Clinical Trials Site Recruiting   Benzinga
08:28AM EDT  The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business   Benzinga
Aug 6, 2021
11:01AM EDT  Credit Suisse Maintains Outperform on Galecto, Lowers Price Target to $7   Benzinga
Aug 5, 2021
08:52AM EDT  Galecto Q2 EPS $(0.49) Up From $(22.83) YoY   Benzinga
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 15, 2021
08:08AM EDT  The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs   Benzinga
Jul 13, 2021
08:06AM EDT  Galecto Resumes Recruitment In Phase 2b Global GALACTIC-1 Trial Of GB0139 For Idiopathic Pulmonary Fibrosis   Benzinga
08:00AM EDT  Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial of   GlobeNewswire Inc
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
Jun 29, 2021
09:00AM EDT  Galecto Biotech US Patent & Trademark Office Abstract Shows Co.'s 'Galactoside inhibitor of galectins' Granted Patent   Benzinga
Jun 22, 2021
12:40PM EDT  Galecto's GB0139 Shows Favorable Safety In COVID-19 Patients, But Plans To Focus On Fibrosis, Cancer Programs   Benzinga
09:29AM EDT  Galecto Reports Prelim. Topline Results From Trial Of Co.'s Inhaled Galectin-3 Inhibitor: 'significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulation'   Benzinga
09:28AM EDT  -- GB0139 significantly reduced oxygen flow requirements and improved several biomarkers for lung and systemic inflammation, liver function, tissue damage and coagulation -- Data demonstrate potential of GB0139 in patients with viral-induced acute lung injury -- Currently Galecto will prioritize resources for its four phase 2 trials in fibrosis and cancer   GlobeNewswire Inc
Jun 10, 2021
02:30PM EDT  Mid-Afternoon Market Update: Nasdaq Rises 100 Points; Materialise Shares Slide   Benzinga
Jun 4, 2021
09:39AM EDT  The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact   Benzinga
Jun 2, 2021
08:00AM EDT  Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that it will host a key opinion leader (KOL) webinar on the myelofibrosis treatment landscape and the current and potential future treatments on Wednesday, June 9, 2021 at 8am Eastern Time.   GlobeNewswire Inc
May 18, 2021
07:44AM EDT  The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO   Benzinga
May 14, 2021
07:59AM EDT  The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts   Benzinga
May 13, 2021
08:10AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use   Benzinga
May 12, 2021
08:57AM EDT  The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron   Benzinga
May 11, 2021
08:00AM EDT  Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Garrett Winslow has joined the Company as Senior Vice President, General Counsel. In this role, Mr. Winslow will lead the Companys legal, compliance and enterprise risk management functions, reporting to Hans Schambye, CEO.   GlobeNewswire Inc
07:54AM EDT  The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings   Benzinga
May 7, 2021
07:40AM EDT  The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs   Benzinga
May 6, 2021
08:00AM EDT  Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that members of the Galecto executive team will participate in multiple upcoming investor events.   GlobeNewswire Inc
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
May 5, 2021
07:43AM EDT  The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues   Benzinga
May 4, 2021
08:37AM EDT  Galecto Q1 Sales $300.10M Down From $365.50M YoY   Benzinga
08:35AM EDT  Galecto Q1 EPS $(0.53) Up From $(21.83) YoY, Sales $300.10M Down From $365.50M YoY   Benzinga
08:34AM EDT  Galecto Q1 EPS $(0.53) Up From $(21.83) YoY   Benzinga
08:30AM EDT  Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the period ended March 31, 2021 and provided a corporate update.   GlobeNewswire Inc
Apr 16, 2021
11:53AM EDT  Galecto Biotech To Be Issued U.S. Patent Titled 'ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS'   Benzinga
Apr 15, 2021
08:07AM EDT  Galecto Highlights Publication Discussing Galectin-3 In Gastric Cancer Journal   Benzinga
08:00AM EDT  Galectin-3 has a key role in Gastric Cancer   GlobeNewswire Inc
Apr 7, 2021
07:58AM EDT  The Daily Biotech Pulse: FibroGen Fudges Safety Data, Novartis Strikes Cancer Drug Collaboration, Immutep Gains On Patent Award   Benzinga
Mar 31, 2021
07:41AM EDT  The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO   Benzinga
Mar 29, 2021
08:30AM EDT  Galecto, Inc. (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced its operating and financial results for the year ended December 31, 2020 and provided a corporate update.   GlobeNewswire Inc
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 24, 2021
08:59AM EDT  The Daily Biotech Pulse: Dynavax-Clover Start Phase 2/3 Vaccine Study. BrainStorm Reports Positive MS Readout, NeoGenomics Goes Shopping   Benzinga
Mar 23, 2021
10:27AM EDT  Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the developmentof novel treatments for fibrosis and cancer, today announced it will host an expert perspectives panel on the evolving treatment landscape for idiopathic pulmonary fibrosis (IPF) and the potential for GB0139 on Tuesday, March 30, 2021 at 2pm Eastern Time.   GlobeNewswire Inc
Mar 19, 2021
07:46AM EDT  The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs   Benzinga
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 16, 2021
09:30AM EDT  Credit Suisse Maintains Outperform on Galecto, Lowers Price Target to $12   Benzinga
08:17AM EDT  The Daily Biotech Pulse: Fulgent Nabs CDC Contract, Enzo Rallies, Solid Biosciences Releases Gene Therapy Data, Moderna Begins Pediatric Vaccine Study   Benzinga
06:14AM EDT  SVB Leerink Maintains Outperform on Galecto, Lowers Price Target to $16   Benzinga
Mar 15, 2021
07:34AM EDT  Galecto Announces Outcome of Data Safety Monitoring Board Interim Review of Phase 2b GALACTIC-1 Study of GB0139 for Idiopathic Pulmonary Fibrosis: DSMB Recommends That The Company Discontinue Dosing and Enrolling Patients   Benzinga
07:30AM EDT  Galecto Announces Outcome of Data Safety Monitoring Board Interim   GlobeNewswire Inc
Mar 4, 2021
08:12AM EST  The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company   Benzinga
Feb 9, 2021
08:00AM EST  Galecto to Present at Upcoming Investor Conferences   GlobeNewswire Inc
Jan 8, 2021
08:09AM EST  Galecto Appoints Anne Prener To Its Board   RTTNews
08:00AM EST  Galecto, Inc., (NASDAQ: GLTO) a NASDAQ listed biotechnology company focused on the developmentof novel treatments for fibrosis and cancer, today announced the appointment of Dr. Anne Prener to its Board of Directors.   GlobeNewswire Inc
Jan 5, 2021
04:40PM EST  Galecto, Inc. Says As Of Dec. 31, 2020 Co.'s Cash, Cash Equivalents And Investments Balance Was About $164M   Benzinga
Jan 4, 2021
04:01PM EST  Galecto, Inc. (NASDAQ: GLTO), a NASDAQ listed biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that Hans Schambye, Chief Executive Officer, will participate in two panel discussions at the LifeSci Partners 10th Annual Healthcare Corporate Access Event, which is being held virtually from January 6-8 and 11-14.   GlobeNewswire Inc
Dec 11, 2020
08:08AM EST  Galecto Q3 EPS $(55.25), Down From $(21.28) YoY   Benzinga
08:06AM EST  Successfully completed listing on US Nasdaq and raised over $150 million during recent IPO and preceding crossover round   GlobeNewswire Inc
Nov 30, 2020
08:05AM EST  Galecto Highlights Publication Of GB0139 Phase 2a Idiopathic Pulmonary Fibrosis Results On European Respiratory Journal, Showing Marked Impact On Several IPF Biomarkers   Benzinga
08:00AM EST  -- The ERJ Paper shows major effects on biomarkers in IPF, linked to mortality and to fall in FVC -- The inhaled GB0139 significantly reduced key plasma biomarkers from baseline vs placebo over 2 weeks -- GB0139 is being investigated in the 450 patients, 52 week GALACTIC-1 Phase 2b/3 trial in IPF   GlobeNewswire Inc
Nov 24, 2020
08:13AM EST  The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia   Benzinga
Nov 23, 2020
04:01PM EST  -- Has extensive experience in pharma and biotech in U.S., Europe and globally -- Galecto completed U.S. initial public offering and plans to initiate three Phase 2 trials in the coming months   GlobeNewswire Inc
07:53AM EST  Credit Suisse Initiates Coverage On Galecto with Outperform Rating, Announces Price Target of $29   Benzinga
07:51AM EST  B of A Securities Initiates Coverage On Galecto with Buy Rating, Announces Price Target of $21   Benzinga
06:39AM EST  SVB Leerink Initiates Coverage On Galecto with Outperform Rating, Announces Price Target of $27   Benzinga
Nov 3, 2020
07:38AM EST  The Daily Biotech Pulse: Aurinia Pulls The Plug On Dry Eye Disease Study, Karyopharm's Positive Readout, Emergency Use Authorization For OraSure   Benzinga
Oct 30, 2020
08:09AM EDT  The Daily Biotech Pulse: Novavax Vaccine Data, Axovant Flags Delay In Parkinson's Study, 2 Biotechs Make Wall Street Debuts   Benzinga
Oct 29, 2020
10:34AM EDT  Galecto Shares Open For Trade At $15; IPO Priced At $15/Share   Benzinga
08:46AM EDT  Galecto Shares Will Open For Quote At 9:50 a.m. EDT, Expected To Open For Trade After 10:00 a.m. EDT, IPO Priced At $15.00/Share   Benzinga
08:45AM EDT  IPOs Happening Today, Thursday, Oct. 29, 2020: LESL, DSACU, GLTO, ALGM   Benzinga
Oct 25, 2020
02:29PM EDT  IPO Outlook: Insurance Cos., Mortgage Providers, Leslie's Pool Supplies Highlight This Week's Offerings   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-5
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC